Evidence map›Paper›PMID 36253045›Full record

ArticleBMJ open2022

Preterm birth and prescriptions for cardiovascular, antiseizure, antibiotics and antiasthmatic medication in children up to 10 years of age: a population-based data linkage cohort study across six European regions.

Mads Damkjaer, Maria Loane, Stine Kjær Urhøj, Elisa Ballardini, Clara Cavero-Carbonell, Alessio Coi, Laura García-Villodre, Joanne Emma Given, Mika Gissler, Anna Heino and 7 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Moderate-to-late prematurity: understanding respiratory consequences and modifiable risk factors.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 11 countries.

Mads DamkjaerPaediatrics, Lillebaelt Hospital - University Hospital of Southern, Vejle, Denmark mads.damkjaer2@rsyd.dk.ORCID 0000-0001-7410-8573
Maria LoaneCentre for Maternal, Fetal and Infant Research, University of Ulster, Newtownabbey, UK.
Stine Kjær UrhøjDepartment of Public Health, University of Copenhagen, Copenhagen K, Denmark.
Elisa BallardiniNeonatal Intensive Care Unit, Paediatric Section, University of Ferrara, Ferrara, Italy.
Clara Cavero-CarbonellRare Diseases Research Unit, Fundacio per al Foment de la Investigacio Sanitaria i Biomedica, Valencia, Spain.ORCID 0000-0002-4858-6456
Alessio CoiNational Research Council Pisa Research Area, Institute of Clinical Physiology, Pisa, Italy.
Laura García-VillodreCenter for Biomedical Research in Network on Rare Diseases, Valencia, Spain.
Joanne Emma GivenFaculty of Life & Health Sciences, Ulster University, Newtownabbey, UK.ORCID 0000-0003-4921-1944
Mika GisslerInformation, THL National Institute for Health and Welfare, Helsinki, Finland.
Anna HeinoFinnish Institute for Health and Welfare, Helsinki, Finland.
Susan JordanNursing, University of Swansea, Swansea, UK.ORCID 0000-0002-5691-2987
Amanda NevilleIMER, University de Ferrara, Florence, Italy.
Anna PieriniNational Research Council, Institute of Clinical Physiology, Pisa, Italy.
Joachim TanPopulation Health Research Institute, St George's, University of London, London, UK.
Ieuan ScanlonFaculty of Medicine, Health and Life Sciences, Swansea University, Swansea, UK.
Ester GarneDepartment of Paediatrics and Adolescent Medicinene, Hospital Lillebaelt Kolding, Kolding, Denmark.ORCID 0000-0003-0430-2594
Joan K MorrisPopulation Health Research Institute, St George's, University of London, London, UK.ORCID 0000-0002-7164-612X
Finnish Institute for Health and Welfare · FIFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESSt George's, University of London · GBSwansea University · GBUniversity of Ferrara · ITUniversity of Ulster · GBIstituto di Fisiologia Clinica · ITKolding Hospital · DKLillebaelt Hospital · DKNational Academies of Sciences, Engineering, and Medicine · USUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPreterm children are exposed to many medications in neonatal intensive care units, but little is known about the effect of prematurity on medication use throughout infancy and childhood. We examined prescriptions of cardiovascular medication (CVM), antiseizure medication (ASM), antiasthmatic medication and antibiotics issued/dispensed in the first 10 years of life for very and moderately preterm children compared with term.

designPopulation-based data linkage cohort study linking information from birth records to prescription records.

settingSix registries from five countries in the EUROlinkCAT study.

participantsThe study population included 1 722 912 children, of whom 10 820 (0.6%) were very preterm (<32 weeks gestational age (GA)), 92 814 (5.4%) were moderately preterm (32-36 weeks GA), 1 606 643 (93.3%) were born at term (≥37 weeks GA) and 0.7% had missing GA. Children with major or minor congenital anomalies were excluded (including patent ductus arteriosus).

main outcome measuresRelative risk (RR) of receiving a prescription for CVM, ASM, antiasthmatic and antibiotics.

resultsVery preterm children had a higher RR of receiving a prescription for CVM and ASM than preterm children. For all preterm children, the RR of having a CVM prescription was 3.58 (95% CI 2.06 to 6.23); 2.06 (95% CI 1.73 to 2.41) for ASM; 1.13 (95% CI 0.99 to 1.29) for antiasthmatics and 0.96 (95% CI 0.93 to 0.99) for antibiotics in the first year of life. Increased prescription of CVM, ASM and antiasthmatics persisted for all 10 years of follow-up. Although the RR was highest for CVM and ASM, in absolute numbers more children received prescriptions for antibiotics (42.34%, 95% CI 38.81% to 45.91%) and antiasthmatics (28.40%, 95% CI 16.07% to 42.649%) than for CVM (0.18%, 95% CI 0.12% to 0.25%) and ASM (0.16%, 95% CI 0.13% to 0.20%) in the first year of life.

conclusionPreterm children had a higher risk of being prescribed/dispensed CVM, ASM and antiasthmatics up to age 10. This study highlights a need for further research into morbidity beyond age 10.

Indexed as

Anti-Asthmatic AgentsPremature BirthAnti-Bacterial AgentsChildCohort StudiesDrug PrescriptionsFemaleHumansInfant, NewbornInformation Storage and RetrievalAnti-Asthmatic AgentsAnti-Bacterial AgentsCongenital heart diseaseNEONATOLOGYPublic health

Identifiers

PMID36253045
PMCPMC9577906
OpenAlexW4306411261

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.